TrialA Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Trial details
- Registry ID
- NCT06329401
- Phase
- Phase 2
AVLN
Avalyn Pharma Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 | AVLN | Phase 2 | Active not recruiting | 2027-06Estimated |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)NCT06951217 | AVLN | Phase 2 | Recruiting | 2031-12-31Estimated |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFNCT07194382 | AVLN | Phase 2 | Recruiting | 2026-12Estimated |
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Trial details
- Registry ID
- NCT06951217
- Phase
- Phase 2
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Trial details
- Registry ID
- NCT07194382
- Phase
- Phase 2
Latest recorded trial changes
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401 · Avalyn Pharma Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382 · Avalyn Pharma Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401 · Avalyn Pharma Inc.
Planned enrollment increased by 75 participants
− Before
300 participants (planned)
+ After
375 participants (planned)
Primary completion date changed
− Before
Apr 2026
+ After
Jun 2027